Stock Scorer

Tango Therapeutics, Inc. (TNGX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 20M 40M 60M Q3 '21: 6.8M Q4 '21: 5.7M Q1 '22: 5.8M Q2 '22: 5.8M Q3 '22: 6.9M Q4 '22: 6.4M Q1 '23: 5.8M Q2 '23: 14.6M Q3 '23: 10.7M Q4 '23: 5.4M Q1 '24: 6.5M Q2 '24: 19.9M Q3 '24: 11.6M Q4 '24: 4.1M Q1 '25: 5.4M Q2 '25: 3.2M Q3 '25: 53.8M Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -19.6M Q4 '21: -22M Q1 '22: -25.4M Q2 '22: -25.2M Q3 '22: -29.9M Q4 '22: -30.6M Q1 '23: -30.3M Q2 '23: -23.2M Q3 '23: -25.6M Q4 '23: -35M Q1 '24: -42.3M Q2 '24: -29.6M Q3 '24: -32.9M Q4 '24: -40.9M Q1 '25: -42.5M Q2 '25: -41M Q3 '25: 14.1M Q4 '25: -41.9M Q1 '26: -48.8M Q2 '26: -59.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -19.6M Q4 '21: -22M Q1 '22: -25.2M Q2 '22: -24.9M Q3 '22: -29.1M Q4 '22: -29.1M Q1 '23: -28M Q2 '23: -20.7M Q3 '23: -22.3M Q4 '23: -30.8M Q1 '24: -37.9M Q2 '24: -25.6M Q3 '24: -29.2M Q4 '24: -37.7M Q1 '25: -39.9M Q2 '25: -38.9M Q3 '25: 15.9M Q4 '25: -38.7M Q1 '26: -45.5M Q2 '26: -55.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -21.5M Q4 '21: -16.9M Q1 '22: -29.7M Q2 '22: -31.5M Q3 '22: -19.6M Q4 '22: -28.3M Q1 '23: -34.9M Q2 '23: -24.5M Q3 '23: -31.1M Q4 '23: -27.5M Q1 '24: -37.9M Q2 '24: -23.6M Q3 '24: -33.4M Q4 '24: -36.6M Q1 '25: -41.7M Q2 '25: -36.5M Q3 '25: -31M Q4 '25: -29.7M Q1 '26: -44.4M Q2 '26: -38.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -22.3M Q4 '21: -17.6M Q1 '22: -31.2M Q2 '22: -33.3M Q3 '22: -22.9M Q4 '22: -29.3M Q1 '23: -35.5M Q2 '23: -25.1M Q3 '23: -31.2M Q4 '23: -27.7M Q1 '24: -38.1M Q2 '24: -23.9M Q3 '24: -33.5M Q4 '24: -36.8M Q1 '25: -41.7M Q2 '25: -37.1M Q3 '25: -31.1M Q4 '25: -29.9M Q1 '26: -44.4M Q2 '26: -38.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '21: 48.5M Q3 '21: 70.2M Q1 '22: 87.7M Q2 '22: 87.8M Q3 '22: 87.9M Q1 '23: 88.2M Q2 '23: 88.4M Q3 '23: 97M Q1 '24: 108.2M Q2 '24: 108.3M Q3 '24: 108.5M Q1 '25: 110.3M Q2 '25: 110.5M Q3 '25: 117.8M Q1 '26: 143.6M Q2 '26: 149.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q3 '21: -0.66 Q4 '21: -0.92 Q1 '22: -0.92 Q2 '22: -1.11 Q3 '22: -1.16 Q4 '22: -1.23 Q1 '23: -1.26 Q2 '23: -1.21 Q3 '23: -1.11 Q4 '23: -1.08 Q1 '24: -1.11 Q2 '24: -1.12 Q3 '24: -1.16 Q4 '24: -1.20 Q1 '25: -1.21 Q2 '25: -1.32 Q3 '25: -0.92 Q4 '25: -0.88 Q1 '26: -0.84 Q2 '26: -0.86 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for TNGX: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.